ArticleAnnals of hematology2020

LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia.

Wei Liu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.